WO2010069141A1 - 具有润滑层结构的双层渗透泵控释片及其制备方法 - Google Patents
具有润滑层结构的双层渗透泵控释片及其制备方法 Download PDFInfo
- Publication number
- WO2010069141A1 WO2010069141A1 PCT/CN2009/001473 CN2009001473W WO2010069141A1 WO 2010069141 A1 WO2010069141 A1 WO 2010069141A1 CN 2009001473 W CN2009001473 W CN 2009001473W WO 2010069141 A1 WO2010069141 A1 WO 2010069141A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- layer
- controlled release
- double
- osmotic pump
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the invention relates to the field of pharmaceutical preparations, in particular to a double-layer osmotic pump controlled release tablet preparation, and to a preparation method of the controlled release tablet. Background technique
- Osmotic pump controlled release tablets are typical Class 0 release controlled release formulations.
- the layer osmotic pump solves the technical problem that the poorly soluble drug is made into the osmotic pump controlled release sheet.
- the problem that the drug cannot be completely released often occurs.
- the basic requirements of the Chinese Pharmacopoeia for controlled release preparations stipulate that the release platform of sustained release preparations should reach more than 90% of the release. At present, many double-layer osmotic pumps have failed to meet this requirement. At the same time, due to the incomplete release of drugs, the therapeutic effects and bioavailability of such drugs are seriously affected.
- PEO polyoxyethylene
- the side wall of the controlled release layer of the osmotic pump controlled release sheet and the non-Newtonian fluid formed by the drug-containing layer are very With a large shear force, the drug layer near the side wall of the semipermeable membrane moves at a speed of almost zero when propelled by the propelling layer, forming a drug release dead angle, which causes the drug to be completely pushed out by the push layer, and the drug cannot be completely released.
- the low bioavailability of the drug has seriously affected the therapeutic effect of the drug.
- the primary object of the present invention is to prepare a two-layer osmotic pump controlled release tablet which can release the drug completely, and improve the release effect of the conventional two-layer osmotic pump controlled release tablet.
- Another object of the present invention is to provide the double layer penetration. Preparation method of pump controlled release tablets.
- a double-layer osmotic pump controlled release tablet comprising: a double-layer core with a drug, a controlled release layer outside the core, and a release hole on the controlled release layer, having lubrication between the core and the controlled release layer Layer structure.
- the drug-containing double-layer core, the controlled release layer and the drug release hole described in the present invention may be conventional, for example, the drug-containing double-layer core is composed of a drug-containing layer and a push layer; On the controlled release layer on one side of the drug layer.
- the drug-containing layer and the push layer described in the present invention may be conventional, and materials for preparing a drug-containing layer and a push layer which are commonly used in the field of controlled release tablets of osmotic pumps are used.
- the material of the push layer comprises a material that swells with water to push the drug layer out of the release orifice of the osmotic pump controlled release sheet.
- the material of the push layer comprises polyethylene oxide ( ⁇ .).
- the material of the push layer further comprises cellulose, preferably hydroxypropyl methylcellulose.
- the drug-containing material comprises povidone.
- the drug-containing layer material also includes cellulose, preferably hydroxypropyl methylcellulose.
- the high substituted hydroxypropylcellulose has a viscosity of from 2.4 to 120 mPa-s, preferably from 12 to 80 mPa's.
- the viscosity of the low viscosity hydroxypropyl methylcellulose is 5 ⁇
- the medicated layer comprises a drug and povidone.
- the drug-containing layer comprises a drug, povidone, and cellulose, preferably hydroxypropylmethylcellulose.
- the propulsion layer comprises polyethylene oxide.
- the pusher layer comprises polyethylene oxide and cellulose, preferably hydroxypropyl methylcellulose.
- the material of the lubricating layer is selected from the group consisting of high-substituted hydroxypropylcellulose or low-viscosity hydroxypropyl fluorenyl ruthenium; and the weight is 0.5% to 6% by weight of the double-layer core.
- the main material of the controlled release layer is cellulose acetate; the weight is 18% ⁇ 24% of the weight of the core layer.
- the release orifice has a diameter between 0.4 and 1.2 mm.
- the invention adds a lubricating layer between the core and the controlled release layer.
- the lubricating layer can be quickly Hydration, into a liquid gel with good fluidity and lubrication effect, forming a lubricating layer between the core and the controlled release layer, reducing the medicated layer and the controlled release layer of the double layer.
- the shear force between the drug-containing layers can be smoothly pushed out by the push layer, and the drug release rate is close to 100% within 24 hours.
- the preparation method of the double-layer osmotic pump controlled release tablet of the invention is as follows: the drug and the auxiliary material are made into a core layer containing the drug, and a lubricating layer is wrapped outside the core, and then the outer layer of the lubricating layer is controlled and released. The layer is then perforated on the side of the drug-containing layer to form a double-layer osmotic pump controlled release tablet. Depending on the needs of the production, it is also possible to selectively apply a conventional film coat to the outer layer of the controlled release layer. The preparation process of the lubricating layer, the controlled release layer and the film coating can be carried out using a high-efficiency coating machine.
- a double-layer core containing a drug is prepared: a material containing a drug layer and a material of a push layer are taken, and a double-layer core is formed by a double-layer tablet machine.
- Preparation of lubricating layer coating liquid Take appropriate amount of lubricating layer material into water or ethanol or any proportion of water-ethanol solution, soak, stir to dissolve.
- the lubricating layer material is selected from the group consisting of highly substituted hydroxypropyl cellulose or low viscosity hydroxypropyl methylcellulose. Since hydroxypropylcellulose and hydroxypropylmethylcellulose are soluble in water and soluble in ethanol, they can be dissolved in any proportion of water-ethanol solution.
- the concentration of the lubricating layer coating liquid is controlled between 2% and 20%.
- the solvent with a high water content has a higher coating temperature at the time of coating, while the solution with a higher ethanol content has a lower temperature, but the cost is higher and there is a safety hazard. Therefore, drugs that are unstable to high temperature cannot be used as coating liquids with high water content, and coating liquids containing higher ethanol can be used, and even ethanol can be used as a solvent; for drugs that are not sensitive to temperature, solvents containing more water can be used. You can even use a solvent system that is completely water.
- Packing layer Take the double layer in the high-efficiency coating machine, coat with the lubricating layer coating liquid, and increase the weight of the lubricating layer coating (that is, the weight of the lubricating layer relative to the weight of the core of the layer) Control is within 0.5% ⁇ 6%.
- the air inlet temperature of the coating machine is controlled between 40 and 65 °C.
- Controlled release layer Take the double-layer sheet with the lubricating layer in the high-efficiency coating machine, coat it with the controlled release layer coating solution, and increase the weight of the controlled release layer (ie the weight of the controlled release layer relative to the double Layer core weight The percentage of the amount is 18% ⁇ 24%, and the inlet air temperature of the coating machine is controlled between 15 ⁇ 35 °C.
- Controlled release layer aging The two-layer sheet with the controlled release layer is taken and dried in a drying device.
- the drying temperature is controlled between 35 °C and 60 °C, and the residual amount of acetone is below 0.05%.
- Film-coated garments can be optionally applied to the outside of a perforated two-layer osmotic pump controlled release tablet using conventional tablet coating techniques.
- the double-layer osmotic pump controlled release sheet of the invention has a lubricating layer added on the basis of the traditional double-layer osmotic pump controlled release sheet, and the lubricating layer is composed of a material which is easy to be hydrated, and the lubricating layer is hydrated to form a gel film having lubricating effect. , has a good lubrication.
- the propelling layer absorbs water and expands, pushing the drug layer upwards, due to the lubricating effect of the lubricating layer, the drug layer can be moved as a whole without dead angles, and the final drug layer is completely pushed out, and the drug is completely released.
- the lubricating layer is composed of high-substituted hydroxypropylcellulose or low-viscosity hydroxypropylmethylcellulose, and the entire double-layer core can be coated with a lubricating layer by a conventional coating method, and the process is simple and easy to operate, but the drug is The release effect is greatly improved, and at the same time, the coating process of the controlled release layer is not affected, and the big problem is solved by the simplest method.
- the two-layer osmotic pump controlled release tablet of the present invention is a nifedipine two-layer osmotic pump controlled release tablet, and the drug in the two-layer tablet core is nifedipine.
- FIG. 1 is a schematic structural view of a two-layer osmotic pump controlled release sheet having a lubricating layer structure of the present invention, wherein: 1-drug layer; 2-pushing layer; 3-lubricating layer; 4-controlled release layer; 5 --release hole. 2 is a graph showing the release effect of Example 1.
- Figure 3 shows the effect of the amount of lubricant on the release
- Figure 4 shows the effect of controlled release membrane weight gain on release.
- Example 1 Nifedipine osmotic pump controlled release sheet with lubricating layer structure.
- the preparation method is as follows.
- Micronization of nifedipine raw material Take nifedipine raw material for micronization treatment, and obtain micronized raw material medicine with particle size below ⁇ ;
- the pressed double-layer sheet is coated on the high-efficiency coating machine with a lubricating layer, the coating process controls the film bed temperature to be 45 ⁇ 2° C., and the lubricating layer has a weight gain of 1%;
- Acetic acid cellulose, polyethylene glycol 1500, dibutyl sebacate are sequentially added to acetone, and the mixture is stirred to disperse. After all the solid matter is swollen, stirring is continued to dissolve, and it is reserved;
- Controlled release layer The coated material of the coated garment is packaged on the high-efficiency coating machine to control the release film. The coating process does not need to heat the material bed, and the weight of the control coating is calculated according to the double-layer core. % ( w/w );
- Controlled release layer aging 'The sheet containing the controlled release layer was placed in an oven at 40 ⁇ 45 °C and aged for 16 hours.
- Laser drilling Remove the aged tablets and use a laser punch to make a release hole in the center of the drug-containing layer with a pore size of 700 ⁇ m.
- the structure of the nifedipine osmotic pump controlled release sheet having the lubricating layer structure is as shown in Fig. 1.
- the two layers are composed of the drug-containing layer 1 and the push layer 2, and the lubricating layer 3 is sequentially arranged outside the double-layer core.
- the controlled release layer 4 has a drug releasing hole 5 on the side of the drug-containing layer of the controlled release sheet.
- the first method for the determination of the release rate is determined by the second method of dissolution.
- the release was determined by HPLC at 100 rpm.
- the chromatographic conditions were: C18 was the stationary phase and the mobile phase was: acetonitrile-methanol-water (20:30:50).
- the measured release, the result is more than 90% release over 24 hours, in line with the general provisions of the Chinese Pharmacopoeia on controlled release formulations.
- the release curve is shown in Figure 2. Time (h) 0 4 8 12 16 24 Release 0.0% 17.3% 40.1% 62.3% 75.8% 96.0%
- Example oo 2 Effect of the amount of lubricating layer on release
- nifedipine osmotic pump controlled release tablets were prepared according to the same materials, dosages and operations as in Example 1, except that the weight gain of the lubricating layer was 0.5% and 6%, respectively, and the influence of the amount of the lubricating layer on the release was evaluated.
- the weight gain of the lubricating layer was 0.5% and 6%, respectively, and the influence of the amount of the lubricating layer on the release was evaluated.
- the 24-hour release is greater than 90%.
- the measured release profile is shown in Figure 3.
- the nifedipine osmotic pump controlled release tablets were prepared according to the same materials, dosages and operations as in Example 1. The difference was that the controlled release film coating weight gain was 18% and 24%, respectively, and the release was in accordance with the Chinese Pharmacopoeia.
- the general provisions for controlled release formulations have a 24-hour release greater than 90%. The measurement results are as follows. The release curve is shown in Figure 4.
- a two-layer sheet was prepared in accordance with the procedure of Example 1, and a lubricating layer coating liquid of two different solvents was prepared in accordance with the following formulation.
- Lubricating layer 1 formula:
- Preparation method Take 5 g of hydroxypropyl methylcellulose, add 75 g of ethanol, stir to dissolve, and set aside;
- Packing layer Take the pressed double layer into two parts in a high-efficiency coating machine and apply it in several parts. ⁇ once the lubrication layer 1 , the second lubrication layer 2 , the coating process control bed temperature is 45 ⁇ 2 ° C, the weight gain of the lubrication layer is about 2%;
- Example 2 Subsequent operations were carried out in accordance with the preparation method of Example 1.
- the weight gain of the controlled release layer was 21.3% and 22.1%, respectively.
- the release rate was determined according to the method of Example 1.
- the release of the nifedipine osmotic pump controlled release tablets prepared by the solvent of the two different lubricating layers was in accordance with the Chinese Pharmacopoeia.
- the general rule of preparation is that the 24-hour release is greater than 90%.
- the measurement results are as follows. The release curve is shown in Figure 5.
- the osmotic pump controlled release tablets with smooth release can be prepared by using water or ethanol as the solvent of the lubricating layer coating solution. There is no significant difference in the release of the two.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801509213A CN102264356A (zh) | 2008-12-16 | 2009-12-16 | 具有润滑层结构的双层渗透泵控释片及其制备方法 |
JP2011541060A JP2012512187A (ja) | 2008-12-16 | 2009-12-16 | 潤滑層構造を有する二層浸透圧ポンプ制御放出錠剤及びその調製方法 |
US13/140,288 US20120015028A1 (en) | 2008-12-16 | 2009-12-16 | Controlled-Released Osmotic Pump Tablet with Lubricating Layer and the Preparation Thereof |
EP09832823.0A EP2380562A4 (en) | 2008-12-16 | 2009-12-16 | OSMOTIC PUMP TABLET WITH CONTROLLED RELEASE AND SLIP LAYER AND ITS MANUFACTURE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810239714.2 | 2008-12-16 | ||
CN2008102397142A CN101703488B (zh) | 2008-12-16 | 2008-12-16 | 具有润滑层结构的双层渗透泵控释片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010069141A1 true WO2010069141A1 (zh) | 2010-06-24 |
Family
ID=42268273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/001473 WO2010069141A1 (zh) | 2008-12-16 | 2009-12-16 | 具有润滑层结构的双层渗透泵控释片及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120015028A1 (zh) |
EP (1) | EP2380562A4 (zh) |
JP (1) | JP2012512187A (zh) |
CN (2) | CN101703488B (zh) |
WO (1) | WO2010069141A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520111A (ja) * | 2011-06-06 | 2014-08-21 | オーク・クレスト・インスティテュート・オブ・サイエンス | ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス |
CN115383331A (zh) * | 2022-09-22 | 2022-11-25 | 上海工程技术大学 | 控释片激光打孔、高精度红外检测装置 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101856337B (zh) * | 2010-05-28 | 2012-10-03 | 中国科学院上海药物研究所 | 一种渗透控释药物传递系统及其制备方法 |
CN102293760B (zh) * | 2011-03-04 | 2015-03-18 | 上海医药集团股份有限公司 | 一种单硝酸异山梨酯择时控释制剂及其制备方法 |
JP6296371B2 (ja) * | 2013-12-23 | 2018-03-20 | ウェン、シャオガンWEN, Xiaoguang | 二層錠剤の調製方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931167A (zh) * | 2006-06-28 | 2007-03-21 | 广州贝氏药业有限公司 | 非洛地平双层渗透泵控释药物组合物 |
US20070166381A1 (en) * | 2006-01-06 | 2007-07-19 | Iran Reyes | Osmotic dosage form with controlled release and fast release aspects |
CN101128190A (zh) * | 2005-02-11 | 2008-02-20 | 西梯茜生命工学股份有限公司 | 含盐酸坦索罗辛的控释制剂 |
CN101167700A (zh) * | 2006-10-24 | 2008-04-30 | 北京红林制药有限公司 | 硝苯地平控释片及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190765A (en) * | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
WO2000025790A1 (en) * | 1998-11-02 | 2000-05-11 | Alza Corporation | Controlled delivery of antidepressants |
RU2246295C2 (ru) * | 1998-11-02 | 2005-02-20 | Элзэ Копэрейшн | Лекарственная форма c постоянной скоростью высвобождения лекарственного вещества, ядро лекарственной формы и способ обеспечения облегченного высвобождения лекарственного вещества из лекарственной формы |
AU2004275835B2 (en) * | 2003-09-26 | 2011-06-23 | Alza Corporation | Controlled release formulations exhibiting an ascending rate of release |
CN100574748C (zh) * | 2003-12-15 | 2009-12-30 | 北京科信必成医药科技发展有限公司 | 择时释放渗透泵控释片 |
JP2007181427A (ja) * | 2006-01-06 | 2007-07-19 | Sanei Gen Ffi Inc | 飲料用起泡剤及び/又は泡安定剤、並びにこれを含有する発泡飲料 |
CN101095681B (zh) * | 2007-07-13 | 2011-04-20 | 沈阳药大制剂新技术有限公司 | 盐酸阿夫唑嗪渗透泵型控释制剂及其制备方法 |
CN101259113B (zh) * | 2008-04-21 | 2013-02-13 | 沈阳药科大学 | 依托度酸渗透泵型控释制剂 |
-
2008
- 2008-12-16 CN CN2008102397142A patent/CN101703488B/zh active Active
-
2009
- 2009-12-16 WO PCT/CN2009/001473 patent/WO2010069141A1/zh active Application Filing
- 2009-12-16 CN CN2009801509213A patent/CN102264356A/zh active Pending
- 2009-12-16 JP JP2011541060A patent/JP2012512187A/ja active Pending
- 2009-12-16 US US13/140,288 patent/US20120015028A1/en not_active Abandoned
- 2009-12-16 EP EP09832823.0A patent/EP2380562A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128190A (zh) * | 2005-02-11 | 2008-02-20 | 西梯茜生命工学股份有限公司 | 含盐酸坦索罗辛的控释制剂 |
US20070166381A1 (en) * | 2006-01-06 | 2007-07-19 | Iran Reyes | Osmotic dosage form with controlled release and fast release aspects |
CN1931167A (zh) * | 2006-06-28 | 2007-03-21 | 广州贝氏药业有限公司 | 非洛地平双层渗透泵控释药物组合物 |
CN101167700A (zh) * | 2006-10-24 | 2008-04-30 | 北京红林制药有限公司 | 硝苯地平控释片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2380562A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520111A (ja) * | 2011-06-06 | 2014-08-21 | オーク・クレスト・インスティテュート・オブ・サイエンス | ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス |
JP2017101035A (ja) * | 2011-06-06 | 2017-06-08 | オーク・クレスト・インスティテュート・オブ・サイエンスOak Crest Institute Of Science | ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス |
JP2018048198A (ja) * | 2011-06-06 | 2018-03-29 | オーク・クレスト・インスティテュート・オブ・サイエンスOak Crest Institute Of Science | ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス |
US9937335B2 (en) | 2011-06-06 | 2018-04-10 | Oak Crest Institute Of Science | Drug delivery device employing wicking release window |
KR102059698B1 (ko) | 2011-06-06 | 2019-12-26 | 오크 크레스트 인스티튜트 오브 사이언스 | 심지 방출창을 도입한 약물 전달 장치 |
CN115383331A (zh) * | 2022-09-22 | 2022-11-25 | 上海工程技术大学 | 控释片激光打孔、高精度红外检测装置 |
Also Published As
Publication number | Publication date |
---|---|
CN101703488A (zh) | 2010-05-12 |
CN101703488B (zh) | 2013-02-20 |
EP2380562A4 (en) | 2013-12-11 |
US20120015028A1 (en) | 2012-01-19 |
CN102264356A (zh) | 2011-11-30 |
JP2012512187A (ja) | 2012-05-31 |
EP2380562A1 (en) | 2011-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW550090B (en) | Stable oral pharmaceutical dosage forms for acid-unstable drug | |
JP5167345B2 (ja) | 薬剤を加速放出する腸溶コーティングを含む固体剤形 | |
JP4963767B2 (ja) | 制御放出性製剤の製法 | |
Wesseling et al. | Drug release from beads coated with an aqueous colloidal ethylcellulose dispersion, Aquacoat®, or an organic ethylcellulose solution | |
EP2510923B1 (en) | Coating composition, solid preparation coated therewith, and method for preparing solid preparation | |
WO2006026504A2 (en) | Mucoadhesive oral formulations of high permeability, high solubility drugs | |
WO2009059510A1 (fr) | Composition pharmaceutique solide sensible au ph pour formulation orale et procede de preparation associe | |
US8753682B2 (en) | Dual release oral tablet compositions of dexlansoprazole | |
WO2010069141A1 (zh) | 具有润滑层结构的双层渗透泵控释片及其制备方法 | |
WO2015154655A1 (zh) | 一种控释片 | |
JP2007332101A (ja) | 腸溶性顆粒剤及びその製造方法 | |
CN103784414A (zh) | 一种埃索美拉唑肠溶片及其制备方法 | |
KR20070094627A (ko) | 비점착제와 함께 미분화된 장용 중합체를 포함하는 장용 막피복 조성물 | |
US9114085B2 (en) | Modified release pharmaceutical compositions of dexlansoprazole | |
US20050106252A1 (en) | Combination of polyvinyl acetate with water-insoluble, acid-insoluble, or alkali-insoluble polymers used for the production of film coatings with highly controlled release and high stability | |
JP2012512187A5 (zh) | ||
Ha et al. | Preparation and evaluation of sustained-release doxazosin mesylate pellets | |
ITFI20070253A1 (it) | Formulazioni farmaceutiche per la somministrazione di ipp. | |
JP5070618B2 (ja) | 腸溶性顆粒剤及びその製造方法 | |
JPH0791184B2 (ja) | 放出制御型製剤およびその製法 | |
CN104758266B (zh) | 一种非洛地平缓释片及其制备工艺 | |
JP2016128391A (ja) | フィルムコーティング液並びに経口固形製剤及びその製造方法 | |
WO2024022382A1 (zh) | 渗透泵控释制剂、渗透泵控释组合物、制备方法和应用 | |
JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
JP5819800B2 (ja) | 高粘度ヒプロメロースを分散したコーティング液及び固形製剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980150921.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09832823 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011541060 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009832823 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13140288 Country of ref document: US |